ASH 2018 | Telomere length as a prognostic tool in CLL: is FCR chemoimmunotherapy the right treatment?
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Telomere length has been shown to be a powerful predictor of outcome following fludarabine, cyclophosphamide and rituximab (FCR)-based treatment in chronic lymphocytic leukemia (CLL). Christopher Fegan, MB, MD, FRCP, FRCPath, of Cardiff University, Cardiff, UK, explains how this knowledge has the potential to identify patients who would benefit from FCR-based chemoimmunotherapy and those who would not. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Fegan discusses how this data removes the unknown.
Get great new content delivered to your inboxSign up